

FLOWCHART OF AN EMBODIMENT OF THE CURRENT INVENTION




FIG. 1

**OVERVIEW OF ANALYTICS PERFORMED WITH KMK917 WITH REGARD
TO HINGE REGION MODIFICATION**




FIG. 2

FIG. 3A CEx-HPLC of isolated KMK antibody samples




FIG. 3B CEx-HPLC of isolated KMK antibody samples – wild type




FIG. 3C CEx-HPLC of isolated KMK antibody samples – wild type




FIG. 3D CEx-HPLC of isolated KMK antibody samples – hinge mutant




FIG. 3E CEx-HPLC of isolated KMK antibody samples – hinge mutant




FIG. 3F CEx-HPLC of isolated KMK antibody samples – mutant (transgenic)




FIG. 3G CEx-HPLC of isolated KMK antibody samples – mutant (transgenic)




FIG. 4A CEx-HPLC of KMK wild type sample \pm Endoglycosidase F treatment, wild type




FIG. 4B CEx-HPLC of KMK wild type sample \pm Endoglycosidase F treatment, wild type




FIG. 4C CEx-HPLC of KMK mutant sample \pm Endoglycosidase F treatment, hinge and CH2 mutant




FIG. 4D CEx-HPLC of KMK wild type sample \pm Endoglycosidase F treatment, hinge and CH2 mutant




FIG. 5A Carbohydrate pattern of KMK917




FIG. 5B KMK917 2012/2014 hinge + Ch2 mutant (HT 5571_4)




FIG. 5C KMK917, Full Scale

